Colon cancer, fatty acids and anti-inflammatory compounds

Current Opinion in Gastroenterology

Volumn 23, Issue 1, 2007, Pages 48-54

  Chapkin, Robert S ^a,b   McMurray, David N ^a   Lupton, Joanne R ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Chemoprotection; Colon cancer; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Inflammatory bowel disease

Indexed keywords

CD59 ANTIGEN; CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LIPOXIN; MEMBRANE PHOSPHOLIPID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR;

CANCER RISK; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLON CARCINOGENESIS; COLORECTAL CANCER; DENDRITIC CELL; DIETARY INTAKE; DISEASE ASSOCIATION; ENTERITIS; HUMAN; LIPID RAFT; PROSTAGLANDIN METABOLISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL AVERAGED ELECTROCARDIOGRAPHY;

ANTI-INFLAMMATORY AGENTS; COLONIC NEOPLASMS; FATTY ACIDS, OMEGA-3; HUMANS;

EID: 33845288291     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32801145d7     Document Type: Review

References (105)

1. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role in inflammation. Am J Physiol 2004; 287:G7-G17.
2. Minoura T, Takata T, Sakaguchi M, et al. Effect of dietary eicosapentaenoic acids on azoxymethane-induced colon carcinogenesis in rat. Cancer Res 1988; 48:4790-4794.
3. Deschner EE, Lytle J, Wong G, et al. The effect of dietary omega-3 fatty acids (fish oil) on azoxymethanol-induced focal areas of dysplasia and colon tumor incidence. Cancer 1990; 66:2350-2356.
4. Willet WC, Stampfer MJ, Colditz GA, et al. Relations of meat, fat and fiber intake to the risk of colon cancer in the prospective study among women. N Engl J Med 1990; 323:1664-1672.
5. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993; 15:499-545.
6. Reddy BS. Chemoprevention of colon cancer by dietary fatty acids. Cancer Metastasis Rev 1994; 13:285-302.
7. Anti M, Giancarlo M, Armelao F, et al. Effect of ω-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992; 103:883-891.
8. Anti M, Armelao F, Marra G, et al. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 1994; 107:1709-1718.
9. Caygill CP, Charlett A, Hill MJ. Fat, fish, fish oil and cancer. Br J Cancer 1996; 74:159-164.
10. Chang WC, Chapkin RS, Lupton JR. Predictive value of proliferation, differentiation and apoptosis intermediate markers for colon tumorigenesis. Carcinogenesis 1997; 18:721-730.
11. Cheng J, Ogawa K, Kuriki K, et al. Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett 2003; 193:17-24.
12. Reddy BS, Burill C, Rigotty J. Effect of diets high in ω-3 and ω-6 fatty acids on initiation and postinitiation stages of colon carcinogenesis. Cancer Res 1991; 51:487-491.
13. Whelan J, McEntee MF. Dietary (n-6) PUFAs and intestinal tumorigenesis. J Nutr 2004; 134:3421S-3426S.
14. Hong MY, Lupton JR, Morris JS, et al. Dietary fish oil reduces DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. Cancer Epidemiol Biomarkers Prev 2000; 9:819-826.
15. 2 release in healthy subjects. Gastroenterology 1993; 105:1317-1322.
16. Davidson LA, Lupton JR, Jiang YH, et al. Carcinogen and dietary lipid regulate ras expression and localization in rat colon without affecting farnesylation kinetics. Carcinogenesis 1999; 20:785-791.
17. Davidson LA, Nguyen DV, Hokanson RM, et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 2004; 64:6797-6804.
18. Spector AA. Essentiality of fatty acids. Lipids 1999; 34:S1-S3.
19. Mudter J, Neurath MF. Mucosal T cells: mediators or guardians of inflammatory bowel disease? Curr Opin Gastroenterol 2003; 19:343-349.
20. Podolsky DK. Inflammatorybowel disease. N Engl J Med 2002;347:417-429.
21. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116:609-614.
22. Belluzzi A, Boschi S, Brignola C, et al. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 2000; 71:339S-342S.
23. MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82:611-619.
24. Prescott SM, Stenson WF. Fish oil fix. Nat Med 2005; 11:596-598.
25. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91:439-446.
26. Hu FB, Cho E, Rexrode KM, et al. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003; 107:1852-1857.
27. Stulnig TM. Immunomodulation by polyunsaturated fatty acids: mechanisms and effects. Int Arch Allergy Immunol 2003; 132:310-321.
28. Lupton RS, Chapkin RS. Chemopreventive effects of omega-3 fatty acids. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention I: Promising cancer chemopreventive agents. Totowa: Humana Press; 2004. pp. 591-608.
29. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135:2503-2506.
30. Anderson RE, Sperling L. Lipids of ocular tissues. VII. Positional distribution of the fatty acids in the phospholipids of bovine retina rod outer segments. Arch Biochem Biophys 1971; 144:673-677.
31. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126:1-27.
32. Katan MB, Deslypere JP, Van Birgelen AP, et al. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997; 38:2012-2022.
33. Vidgren HM, Agren JJ, Schwab U, et al. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 1997; 32:697-705.
34. Ma DW, Seo J, Switzer KC, et al. n-3 PUFAs and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 2004; 15:700-706.
35. Ma DW, Seo J, Davidson LA, et al. n-3 PUFAs alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J 2004; 18:1040-1042.
36. Seo J, Barhoumi R, Johnson AE, et al. Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins. FASEB J 2006; 20:770-772. A study demonstrating that the selective suppression of plasma membrane targeting by n-3 PUFAs may constitute a novel mechanism responsible for the long appreciated chemoprotective and immunomodulatory effects of dietary fish oil and DHA.
37. Stillwell W, Shaikh SR, LoCascio D, et al. Docosahexaenoic acid. An influential membrane-altering omega-3 fatty acid. In: Huang JD, editor. Frontiers in nutrition research. Hauppauge: Nova Science; 2006. pp. 249-271.
38. Subbaramaiah K, Yoshimatsu K, Scher E, et al. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. J Biol Chem 2004; 279:12647-12658.
39. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280:3217-3223.
40. 2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005; 280:26565-26572.
41. Buchanan FG, DuBois RN. Connecting Cox-2 and Wnt in cancer. Cancer Cell 2006; 9:6-8.
42. 2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006; 281:2676-2682.
43. 2 promotes antiogenesis in colorectal cancer. J Exp Med 2006; 203:941-951.
44. Lee DY, Lupton JR, Aukema HM, et al. Dietary fat and fiber alter rat colonic mucosal lipid mediators and cell proliferation. J Nutr 1993; 123:1808-1817.
45. Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005; 17:174-182. A thorough review contrasting the COX-dependent metabolism of EPA and arachidonic acid.
46. Bagga D, Wang L, Farias-Eisner R, et al. Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003; 100:1751-1756.
47. Yang P, Chan D, Felix E, et al. Formation of antiproliferative effect of prostaglandin E3 from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 2004; 45:1030-1039.
48. Mortreau O, Morham SG, Sellon R, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase 2. J Clin Invest 2000; 105:469-478.
49. 2 production by stromal cells in the murine small intestine lamina propria: directing the tone of intestinal immune response. J Immunol 2001; 166:4465-4472.
50. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109:883-893.
51. Meyer AM, Ramzan NN, Heigh RI, et al. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006; 51:168-172.
52. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:196-202.
53. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A 1983; 80:3581-3584.
54. Chapkin RS, Akoh CC, Miller CC. Influence of dietary n-3 fatty acids on macrophage glycerophospholipid molecular species and peptidoleukotriene synthesis. J Lipid Res 1991; 32:1205-1213.
55. Cuzzocrea S, Rossi A, Mazzon E, et al. 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 2005; 1-15.
56. 4 induces β-catenin signaling and its association with antiapoptotic bcl-2 in intestine epithelial cells. J Biol Chem 2006; 281:6776-6784.
57. Miller CC, Ziboh VA, Wong T, et al. Dietary supplementation with oils rich in (n-3) and (n-6) fatty acids influences in vivo levels of epidermal lipoxygenase products in guinea pigs. J Nutr 1990; 1210:36-44.
58. Zuo X, Wu Y, Morris JS, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2006; 25:1225-1241.
59. Kelavkar UP, Glasgow W, Olson SJ, et al. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 2004; 6:821-830.
60. Gewirtz AT, Collier-Hyams LS, Young AN, et al. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 2002; 168:5260-5267.
61. Mangino MJ, Brounts L, Harms B, et al. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 2006; 79:84-92.
62. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6:1191-1197.
63. Flower RJ, Perretti M. Controlling inflammation: a fat chance. J Exp Med 2005; 201:671-674.
64. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102:7671-7676. This study suggested that resolvin E1, derived from EPA, may have utility in treating IBD in humans.
65. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998; 95:681-686.
66. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 2000; 97:11280-11285.
67. Cao Y, Dave KB, Doan TP, et al. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 2001; 61:8429-8434.
68. 2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 2005; 11:2265-2271.
69. Bedi A, Pasricha PJ, Alchtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55:1811-1816.
70. Fan YY, Ly LH, Barhoumi R, et al. Dietary docosahexaenoic acid suppresses T cell protein kinase Cθ lipid raft recruitment and IL-2 production. J Immunol 2004; 173:6151-6160.
71. + T-cells. J Lipid Res 2004; 45:1482-1492.
72. Hong MY, Chapkin RS, Barhoumi R, et al. Fish oil increases mitochondrial phospholipids unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis 2002; 23:1919-1925.
73. Sanders LM, Henderson CE, Hong MY, et al. An increase in reactive oxygen species by dietary fish oil coupled with the attenuation of antioxidant defenses by dietary pectin enhances rat colonocyte apoptosis. J Nutr 2004; 134:3233-3238.
74. Ng Y, Barhoumi R, Tjalkens RB, et al. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 2004; 26:1914-1921.
75. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk. JAMA 2006; 295:403-415.
76. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferators-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61:2424-2428.
77. Marin HE, Peraza MA, Billin AN, et al. Ligand activation of peroxisome proliferators-activated receptor b inhibits colon carcinogenesis. Cancer Res 2006; 66:4394-4401.
78. Adachi M, Kurotani R, Morimura K, et al. PPAR gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006; 55:1067-1069. These studies demonstrate that PPARγ has an endogenous role in protection against dextran sodium sulfate-induced colitis and that certain putative PPARγ agonists may act through a PPARγ-independent pathway to suppress colonic inflammation.
79. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response by PPARγ. Nature 2005; 437:759-763.
80. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997; 94:4312-4317.
81. Kliewer SZ, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997; 94:4318-4323.
82. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999; 3:397-403.
83. Fan YY, Spencer TE, Wang N, et al. Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis 2003; 24:1541-1548.
84. Egan LJ, Eckmann L, Greten RR, et al. IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004; 101:2452-2457.
85. Greten FR, Eckmann L, Greten TF, et al. IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-296
86. h2-mediated inflammatory bowel disease with NF-κB decoy oligonucleotides. J Clin Invest 2005; 115:3057-3071.
87. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441:431-436. A comprehensive review on NF-κB, linking inflammation and immunity to cancer development and progression.
88. Yan SR, Joseph RR, Rosen K, et al. Activation of NF-κB following detachment delays apoptosis in intestinal epithelial cells. Oncogene 2005; 24:6482-6491.
89. Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 2006; 130:67-87.
90. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278:43807-43817.
91. Novak TE, Babcock TA, Jho DH, et al. NF-κB inhibition by ω-3 fatty acids modulates LPS-stimulated macrophage TNF-α transcription. Am J Physiol 2003; 284:L84-L89.
92. Camandola S, Leonarduzzi G, Musso T, et al. Nuclear factor κB is activated by arachidonic acid but not by eicosapentaenoic acid. Biochem Biophys Res Commun 1996; 229:643-647.
93. Becuwe P, Bianchi A, Didelot C, et al. Arachidonic acid activates a functional AP-1 and an inactive NF-κB complex in human HepG2 hepatoma cells. Free Radic Biol Med 2003; 35:636-647.
94. Lee JY, Plakidas A, Lee WH, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003; 44:479-486.
95. Weatherill AR, Lee JY, Zhao L, et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol 2005; 174:5390-5397.
96. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005; 6:507-514. This study elegantly demonstrates that intestinal epithelial cells 'condition' mucosal dendritic cells, resulting in the induction of 'noninflammatory' dendritic cells. This control of immune responses appears to be lost in patients with Crohn's disease.
97. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006; 7:456-462.
98. Harder T, Engelhardt KR. Membrane domains in lymphocytes - from lipid rafts to protein scaffolds. Traffic 2004; 5:265-275.
99. Gaus K, Chklovskaia E, St Groth B, et al. Condensation of the plasma membrane at the site of T lymphocyte activation. J Cell Biol 2005; 171:121-131.
100. Shaikh SR, Caffrey CV, Stillwell W, et al. Interaction of cholesterol with docosa-hexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation? Biochemistry 2003; 42:12028-12037.
101. Shaikh SR, Dumaual AC, Castillo A, et al. Oleic and docosahexaenoic acid differentially phase separate from lipid raft molecules: a comparative NMR, DSC, AFM, and detergent extraction study. Biophys J 2004; 87:1752-1766.
102. Geyeregger R, Zeyda M, Zlabinger GJ, et al. Polyunsaturated fatty acids interfere with formation of the immunological synapse. J Leuk Biol 2005; 77:680-688. A cell culture based study indicating that n-3 and n-6 PUFAs are capable of altering immunological synapse formation.
103. Zeyda M, Saemann MD, Stuhlmeir KM, et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-κB activation. J Biol Chem 2005; 280:14293-14301.
104. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98:736-747.
105. Bresalier R, Sandler RS, Quan H, et al. Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.